Letendre will be responsible for spearheading the clinical, regulatory, IP and strategic direction of the company.
Based on data from a pilot proof of concept (POC) study in patients with obstructive sleep apnea (OSA), Letendre’s initial efforts will be to raise additional capital to continue the clinical development of its lead compound, PP-001 for the treatment of OSA.
Prior to joining Pier Pharma, Pete was the president and founder of Greyhound Pharmaceutical Consulting, chief commercial officer at Replidyne, and divisional vice-president and general manager of the hypertension and infectious disease franchises at Abbott Laboratories.
Pier Pharma Board chairman Ken Cohen said Pete brings a wealth of successful experience across all aspects of the pharmaceutical business.
"The Board is confident he’ll be an outstanding and effective leader as we move forward in the development of our sleep apnea drug candidate and the growth of the company," Cohen said.